Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Pipeline Review, H2 2019’, provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Respiratory, Infectious Disease, Toxicology, Dermatology, Gastrointestinal and Hematological Disorders under development targeting Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)

– The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects

– The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aduro BioTech Inc

Bolder Biotechnology Inc

Celdara Medical LLC

Profarma

Savara Inc

Targovax ASA

XL-protein GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Overview

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Companies Involved in Therapeutics Development

Aduro BioTech Inc

Bolder Biotechnology Inc

Celdara Medical LLC

Profarma

Savara Inc

Targovax ASA

XL-protein GmbH

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Drug Profiles

BBT-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMJG-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVAX Vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONCOS-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for RSV Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Melanoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-150 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Dormant Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Product Development Milestones

Featured News & Press Releases

Jul 15, 2019: Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Jul 08, 2019: Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in Anti-PD1 refractory melanoma

Jun 12, 2019: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

Jun 03, 2019: Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination

May 23, 2019: Targovax to fully focus on ONCOS Oncolytic virus program

May 23, 2019: Targovax approval and publication of supplemental prospectus

May 08, 2019: Savara Pharmaceuticals: Investigating GM-CSF in aPAP - A logical replacement of a dysfunctional protein

May 08, 2019: Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma

May 06, 2019: Savara announces Molgradex received Fast Track Designation by FDA for treatment of autoimmune pulmonary alveolar proteinosis

Apr 01, 2019: Savara initiates phase 2a clinical study of Molgradex for the treatment of NTM lung infection in people living with cystic fibrosis

Feb 11, 2019: First patient treated in dose expansion cohort of Targovax's ONCOS-102 trial in melanoma

Dec 12, 2018: Targovax presents at DNB 9th Annual Nordic Healthcare Conference

Nov 02, 2018: Savara completes enrolment for Phase IIa Molgradex trial

Oct 24, 2018: Bolder BioTechnology to present preclinical data of BBT-007 at Acute Radiation Syndrome Meeting

Oct 15, 2018: Savara completes enrollment in pivotal Molgradex impala clinical study for the treatment of aPAP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Aduro BioTech Inc, H2 2019

Pipeline by Bolder Biotechnology Inc, H2 2019

Pipeline by Celdara Medical LLC, H2 2019

Pipeline by Profarma, H2 2019

Pipeline by Savara Inc, H2 2019

Pipeline by Targovax ASA, H2 2019

Pipeline by XL-protein GmbH, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports